Lupin settles patent infringement dispute with Astellas, to continue selling overactive bladder drug Mirabegron

Under the agreement, Lupin will pay Astellas $90 million, which includes a prepaid option payment of $75 million, and a prepaid per unit license fee for each unit of its product sold through September 2027Under the agreement, Lupin will pay Astellas $90 million, which includes a prepaid option payment of $75 million, and a prepaid per unit license fee for each unit of its product sold through September 2027 https://www.thehindu.com/business/Industry/lupin-settles-patent-infringement-dispute-with-astellas-to-continue-selling-overactive-bladder-drug-mirabegron/article70614060.ece 2026-02-10T06:34:53.000Z Industry {}